Sage Therapeutics Revenue and Competitors

Boston, MA USA

Location

$1.1B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Sage Therapeutics's estimated annual revenue is currently $97.7M per year.(i)
  • Sage Therapeutics received $575.0M in venture funding in February 2018.
  • Sage Therapeutics's estimated revenue per employee is $127,148
  • Sage Therapeutics's total funding is $1.1B.

Employee Data

  • Sage Therapeutics has 768 Employees.(i)
  • Sage Therapeutics grew their employee count by 4% last year.

Sage Therapeutics's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
Executive Director, AccountingReveal Email/Phone
3
SVP Regulatory AffairsReveal Email/Phone
4
SVP, Global Medical AffairsReveal Email/Phone
5
VP, Market Access Field and Field SalesReveal Email/Phone
6
Head US Commercial Compliance, Collaboration Compliance, & Compliance Ops (Exec. Director)Reveal Email/Phone
7
Director- Global Commercial Business Management, Chief StaffReveal Email/Phone
8
SVP, External AffairsReveal Email/Phone
9
Head HEOR Strategic OperationsReveal Email/Phone
10
VP Regulatory AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Sage Therapeutics?

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$1.1B

Total Funding

768

Number of Employees

$97.7M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sage Therapeutics News

2022-04-20 - Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health,...

2022-04-19 - Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Recommendation of “Hold” from Brokerages. Posted by admin on Apr 18th, 2022.

2022-04-06 - Sage Therapeutics Announces Presentation of Promising ...

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to...

2021-03-17 - Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 17, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-label SHORELINE Study. This clinical study was designed to naturalistically fol ...

2020-12-31 - Sage Therapeutics, Inc. announced that it has received $649.986998 million in funding from Biogen MA Inc.

On December 31, 2020, Sage Therapeutics, Inc. (NasdaqGM:SAGE) closed the transaction. The company raised $649,986,998 pursuant to Regulation D.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$159.7M77011%N/A
#2
$151.1M77110%N/A
#3
$382.5M7748%N/A
#4
$75M8199%N/A
#5
$170.6M823-11%$90M

Sage Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-17$20.0MBARCH Venture PartnersArticle
2014-01-23$10.0MUndisclosedArticle
2014-03-14$38.0MCMultipleArticle
2015-04-15$115.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-04-22$138.0MUndisclosedJ.P. Morgan Securities LLCArticle
2017-11-15$345.0MUndisclosedJ.P. Morgan Securities LLCArticle
2018-02-09$575.0MUndisclosedJ.P. Morgan Securities LLCArticle